© 2020 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Leukemias
What Is the Role of Allogeneic-SCT in Adult Acute Lymphoblastic Leukemia in the Era of Targeted Therapies?
October 21, 2020
There are several indications for the use of allo-SCT in adults. With the implementation of targeted therapies, these are continuously changing.
Acute Lymphoblastic Leukemia in Older Adults: Is Chemotherapy-Free Treatment in the Future?
October 18, 2020
Investigation of intensive chemotherapy regimens has unfortunately resulted in a lack of improvement in outcomes for patients with acute lymphoblastic leukemia in the second of the bimodal peaks.
Targeted Agents Induce Significant Efficacy in Older, Frail Patients With ALL
October 17, 2020
On the treatment of adult patients with acute lymphoblastic leukemia, long-term cure rates in elderly populations, or those older than 55 to 60 years of age, are approximately 15% to 20% and represent a clinically unmet need in this hematologic cancer.
Modified Pediatric Regimen Improves Outcomes in Young Adult Patients With Acute Lymphoblastic Leukemia
September 09, 2020
Using a modified pediatric regimen to treat adolescents and young adults with acute lymphoblastic leukemia led to superior outcomes compared with historical adult ALL regimen results, according to a retrospective analysis that evaluated 95 AYAs aged 14 to 39 years. Findings were presented at the eighth annual Society of Hematologic Oncology virtual meeting.
Considerations for Choosing Between Newer Agents in R/R B-Cell ALL
September 09, 2020
In the past 5 years, 3 new treatment options have emerged to treat patients with relapsed or refractory acute lymphoblastic leukemia, providing hope for patients with this disease, but also raising clinical questions of how to choose among these agents and what is the best option for the patient at which time.
CC-486 Constitutes Standard of Care for Subset of Patients with AML
September 05, 2020
In an interview with Targeted Oncology Guillermo Garcia-Manero, MD, discussed the key findings from the QUAZAR AML-001 study and the importance of the FDA approval of CC-486 in post-remission acute myeloid leukemia.
FDA Approves CC-486 as Maintenance Therapy in Acute Myeloid Leukemia
September 01, 2020
The FDA granted approval to the oral hypomethylating agent, CC-486 (azacitidine tablets, Onureg), as a maintenance treatment for adult patients with acute myeloid leukemia who achieved a first complete remission or with incomplete blood count recovery after intensive induction chemotherapy and who are unable to complete intensive curative therapy.
Novel STAMP Inhibitor Asciminib Meets Primary End Point in Phase 3 Study of Chronic Myeloid Leukemia
August 26, 2020
The primary end point of statistically superiority in major molecular response rate at 24 weeks was met with asciminib versus bosutinib as treatment of patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase in the phase 3 ASCEMBL study.
Azacitidine Plus APR-246 Appears Promising as Treatment of TP53-Mutant MDS and AML
August 24, 2020
Thomas Cluzeau, MD, PhD, discusses the rationale for evaluating azacitidine in combination with APR-246 in patients with TP53-mutant myelodysplastic syndrome and acute myeloid leukemia.
Treatment Landscape for Acute Myeloid Leukemia Appears Hopeful for Patients
July 31, 2020
Eunice Wang, MD, discusses the excitement she has experienced in the treatment landscape of acute myeloid leukemia over the last several years due to the number of new treatment options approved by the FDA.